secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001213900-24-106919
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio extends shareholder rights plan to Dec 2025 and grants stock options to executives and directors
--------------------------------------------------------------------------------

- Rights Agreement amended to extend expiration to December 30, 2025.
- Non-employee directors each granted options for 32,500 shares at $5.05, vesting Dec 5, 2026.
- CEO Raymond Tesi granted options for 226,000 shares at $5.05, vesting Dec 5, 2026.
- CFO David Moss granted 223,000 options; CSO Mark Lowdell 140,000 options, same terms.
- All grants expire December 4, 2034 and were made under the 2021 Stock Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/0001213900-24-106919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024106919/ea0223776-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-106919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer